Filtered By:
Therapy: Statin Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 12097 results found since Jan 2013.

Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol
CONCLUSION: Inclisiran is an effective and safe medication for lowering LDL-C levels. Additional data regarding efficacy on cardiovascular outcomes and long-term safety profile with inclisiran are needed.PMID:35775133 | DOI:10.1177/10600280221105169
Source: The Annals of Pharmacotherapy - July 1, 2022 Category: Drugs & Pharmacology Authors: Essie Samuel Maya Watford Ugochukwu O Egolum David N Ombengi Hua Ling Drew W Cates Source Type: research

The growth of siRNA-based therapeutics: updated clinical studies.
Abstract More than two decades after the natural gene-silencing mechanism of RNA interference was elucidated, small interfering RNA (siRNA)-based therapeutics have finally broken into the pharmaceutical market. With three agents already approved and many others in advanced stages of the drug development pipeline, siRNA drugs are on their way to becoming a standard modality of pharmacotherapy. The majority of late-stage candidates are indicated for rare or orphan diseases, whose patients have an urgent need for novel and effective therapies. Additionally, there are agents that have the potential to meet the need of...
Source: Biochemical Pharmacology - January 26, 2021 Category: Drugs & Pharmacology Authors: Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong XB Tags: Biochem Pharmacol Source Type: research

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1.
Conclusions -Inclisiran produces significant and prolonged reductions in atherogenic lipoproteins, suggesting that inhibiting synthesis of PCSK9 through siRNA may be a viable alternative to other approaches which target PCSK9. Clinical Trial Registration -URL: https://www.clinicaltrials.gov. Unique identifier: NCT02597127. PMID: 29735484 [PubMed - as supplied by publisher]
Source: Circulation - May 7, 2018 Category: Cardiology Authors: Ray KK, Stoekenbroek RM, Kallend D, Leiter LA, Landmesser U, Wright RS, Wijngaard P, Kastelein JJ Tags: Circulation Source Type: research

Self-amplified ROS production from fatty acid oxidation enhanced tumor immunotherapy by atorvastatin/PD-L1 siRNA lipopeptide nanoplexes
Biomaterials. 2022 Nov 3;291:121902. doi: 10.1016/j.biomaterials.2022.121902. Online ahead of print.ABSTRACTDespite the important role of reactive oxygen species (ROS) in battling cancer, ROS production with current approaches has been severely limited by the deficiency of oxy-substrates in tumor microenvironment. Herein, an atorvastatin (Ato)-catalytic self-amplified approach was utilized for sustainable ROS production and enhancing anti-tumor efficacy of PD-L1 silencing. A C18-pArg8-ss-pHis10 lipopeptide based self-assembled nanoplexes was developed to co-encapsulate AMP-activated protein kinase (AMPK) activator of Ato a...
Source: Biomaterials - November 13, 2022 Category: Materials Science Authors: Yan Gao Zilin Song Li Jia Yi Tang Chengcheng Wang Xiuli Zhao Haiyang Hu Dawei Chen Mingxi Qiao Source Type: research

VE-statin/Egfl7 siRNA inhibits angiogenesis in malignant glioma in vitro.
This study investigated the role of VE-statin/Egfl7 and its mechanism in angiogenesis in malignant glioma. Transwell culture plates were used to establish an U251-HUVEC co-culture system, which was used to mimic the interaction between malignant glioma and endothelial cells. Lentiviral vectors expressing VE-statin/Egfl7 siRNA were constructed, and U251 cells and HUVECs were transfected to inhibit VE-statin/Egfl7 expression. The proliferation, adherence, migration, and lumen formation of endothelial cells were assayed to investigate the influence of VE-statin/Egfl7 on angiogenesis in malignant glioma in vitro. Data showed t...
Source: International Journal of Clinical and Experimental Pathology - April 7, 2014 Category: Pathology Authors: Huang C, Yuan X, Li Z, Tian Z, Zhan X, Zhang J, Li X Tags: Int J Clin Exp Pathol Source Type: research

The Potential Impact of Statins in the Treatment of Patients with COVID-19 Infection
CONCLUSION: Patients with SARS-CoV-2 infection have a high risk of cardiovascular and thrombotic complications and pleiotropic effects of statins may help manage the COVID-19. There is growing evidence that supports the need for trials of statin treatment in COVID-19 infection.PMID:35132599 | DOI:10.1007/978-3-030-85109-5_9
Source: Atherosclerosis - February 8, 2022 Category: Cardiology Authors: Reza Jafarzadeh Esfehani Mohammad Vojdanparast Saman Soleimanpour Gordon A Ferns Amir Avan Source Type: research

Estimating the potential impact of LDL-C lowering through SIRNA therapies on population health: A simulation study
Background and Aims: Inclisiran, an siRNA therapy, provides sustained reductions in LDL-C. Potential CV benefits of inclisiran, as an adjunct to statins, were evaluated through simulation.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: K. Ray, L. Gunn, L.G. Conde, F. Raal, R.S. Wright, N. Gosselin, L. Leiter, W. Koenig, G. Schwartz, U. Landmesser Source Type: research

The Potential Impact of Statins in the Treatment of Patients with COVID-19 Infection
CONCLUSION: Patients with SARS-CoV-2 infection have a high risk of cardiovascular and thrombotic complications and pleiotropic effects of statins may help manage the COVID-19. There is growing evidence that supports the need for trials of statin treatment in COVID-19 infection.PMID:35132599 | DOI:10.1007/978-3-030-85109-5_9
Source: Advances in Experimental Medicine and Biology - February 8, 2022 Category: Research Authors: Reza Jafarzadeh Esfehani Mohammad Vojdanparast Saman Soleimanpour Gordon A Ferns Amir Avan Source Type: research

Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery.
CONCLUSIONS: Evidence was insufficient to allow review authors to conclude that statin use resulted in either a reduction or an increase in any of the outcomes examined. The existing body of evidence leaves questions about the benefits of perioperative use of statins for vascular surgery unanswered. Widespread use of statins in the target population means that it may now be difficult for researchers to undertake the large RCTs needed to demonstrate any effect on the incidence of postoperative cardiovascular events. However, participant-reported outcomes have been neglected and warrant further study. PMID: 23824754 [Pu...
Source: Cochrane Database of Systematic Reviews - July 3, 2013 Category: Journals (General) Authors: Sanders RD, Nicholson A, Lewis SR, Smith AF, Alderson P Tags: Cochrane Database Syst Rev Source Type: research

HMG CoA reductase inhibitors (statins) for dialysis patients.
CONCLUSIONS: Statins have little or no beneficial effects on mortality or cardiovascular events and uncertain adverse effects in adults treated with dialysis despite clinically relevant reductions in serum cholesterol levels. PMID: 24022428 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - September 11, 2013 Category: Journals (General) Authors: Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, Hegbrant J, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research